Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 48 million and 62 million yuan for 2024, representing a decrease of 90.53% to 87.76% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 20 million and 30 million yuan, down 94.67% to 92.01% from the previous year[3] - The impact of non-recurring gains and losses on the net profit attributable to shareholders is estimated to be between 28 million and 32 million yuan, primarily from government subsidies, a decrease of 75.59% to 78.64% year-on-year[5] Revenue and Profit Decline Factors - The overall revenue and profit of the company are declining due to factors such as falling terminal market prices, intensified competition, and rising production costs[5] Audit and Financial Data - The financial data in this earnings forecast has not been audited by registered accountants, but there are no disagreements with the annual audit firm regarding the earnings forecast[4]
红日药业(300026) - 2024 Q4 - 年度业绩预告